18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosed of neuroendocrine neoplasms.
Suspected of neuroendocrine neoplasms.

Exclusion criteria

Inability to undergo biopsy/surgical treatment.
Concurrent active malignancy.
Severe uncontrolled comorbidities/active infections.
Inability to provide informed consent.

Treatment and study plan

18F-AlF-NOTA-Octreotide PET-CT or PET-MR

Diagnostic Test

18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Primary outcomes

Diagnostic efficacy

Time frame: through study completion, an average of 1.5 year

Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms

Other outcomes

Prognostic Value of Baseline 18F-OC PET for Progression-Free Survival (PFS) in High-Risk Patients

Time frame: through study completion, 3-4 years

This measure evaluates the association between baseline 18F-OC PET parameters (e.g., SUVmax, SUVmean, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and progression-free survival (PFS) in high-risk neuroendocrine neoplasms patients. PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model.

Study contacts

Contact information is provided by the study sponsor or research team.

Donghe Chen

CONTACT

[email protected]

0571-87236432

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Zhejiang University

Other

Registry information

Official study title

Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 3, 2025
Registry last updated: Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting